���沙莫瑞林历史与监管定位 — Complete Guide

By Editorial Desk · published 2025-09-04 · last reviewed 2025-09-22 · Wiki

visceral adiposity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-22. Anything still debated is marked as such rather than presented as settled.

特沙莫瑞林历史与监管定位

在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。

特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。

Background and Clinical Development

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Tesamorelin at a glance

Background And Regulatory Development

Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.

Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.

Related pages on this site

• Clear checklist
• Proven briefing
• Verified toolkit
• Comprehensive primer
• Verified notes
• Reliable guide
• Focused primer
• Gradual analysis

Identity and Development Background

Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Background and Pharmacology of Tesamorelin

Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.

Background and Clinical Profile

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

Supporting material

=== European settlement === The first European settlement in South Africa was founded at the Cape of Good Hope in 1652, and administered as part of the Dutch Cape Colony. As a result of political turmoil in the Netherlands, the British occupied the Cape three times during the Napoleonic Wars, and the occupation became permanent after the Battle of Blaauwberg in 1806. The colony was then home to about 26,000 colonists settled under Dutch rule. Most represented old Dutch families brought to the Cape during the late 17th and early 18th centuries. Broadly speaking, the colonists included distinct subgroups, including the Boers. The Boers were itinerant farmers who lived on the colony's frontiers, seeking better pastures for their livestock. Many were dissatisfied with aspects of British administration, in particular with Britain's abolition of slavery in 1834. Boers who used forced labor were unable to collect compensation for their slaves. Between 1836 and 1852, many elected to migrate away from British rule in what became known as the Great Trek. Around 15,000 trekking Boers departed the Cape Colony and followed the eastern coast towards Natal. After Britain annexed Natal in 1843, they journeyed farther north into South Africa's eastern interior. There, they established two independent Boer republics: the South African Republic (1852; also known as the Transvaal Republic) and the Orange Free State (1854).

== Medical uses == Dielectric heating (diathermy) is used in medicine; the frequencies used typically lie in the ultrasonic, shortwave, and microwave ranges. Careless application, especially when the patient has implanted metal conductors (e.g. cardiostimulator leads), can cause burns of skin and deeper tissues and even death. Microwave damage to tissues can be intentionally exploited as a therapeutic technique, e.g. radiofrequency ablation and radiofrequency lesioning. Controlled destruction of tissue is performed for treatment of arrhythmia. Microwave coagulation can be used for some kinds of surgeries, e.g., stopping bleeding after a severe liver injury. Microwave heating seems to cause more damage to bacteria than equivalent thermal-only heating. However food reheated in a microwave oven typically reaches lower temperature than classically reheated, therefore pathogens are more likely to survive. Microwave heating of blood, e.g. for transfusion, is contraindicated, as it can cause hemolysis and hyperkalemia. Microwave heating is one of the methods for inducing hyperthermia for hyperthermia therapy. High-energy microwaves are used in neurobiology experiments to kill small laboratory animals (mice, rats) in order to fix brain metabolites without the loss of anatomical integrity of the tissue. The instruments used are designed to focus most of the power to the animal's head. The unconsciousness and death is nearly instant, occurring in less than one second, and the method is the most efficient one to fix brain tissue chemical activity.

== Further reading == Epstein, Noah; Chandran, Sheena; Chou, Loretta (2012). "Current Concepts Review: Intra-Articular Fractures of the Calcaneus". Foot & Ankle International. 33 (1): 79–86. doi:10.3113/FAI.2012.0079. ISSN 1071-1007. McKinley, Todd O; Borrelli, Joseph; D'Lima, Darryl D; Furman, Bridgette D; Giannoudis, Peter V (2010). "Basic Science of Intra-articular Fractures and Posttraumatic Osteoarthritis". Journal of Orthopaedic Trauma. 24 (9). Ovid Technologies (Wolters Kluwer Health): 567–570. doi:10.1097/bot.0b013e3181ed298d. ISSN 0890-5339. PMC 3662545.

== Politics == The company spends approximately $10 million per year on lobbying in the United States. Political contributions have mostly been to individuals and organizations associated with the Democratic Party. The company is a member of many industry advocacy groups and sponsors many industry events.

The hypothalamus has a central neuroendocrine function, most notably by its control of the anterior pituitary, which in turn regulates various endocrine glands and organs. Releasing hormones (also called releasing factors) are produced in hypothalamic nuclei then transported along axons to either the median eminence or the posterior pituitary, where they are stored and released as needed.

Sources: en.wikipedia.org

Notes from published material

=== Membership policy === WOSM's membership consists of its remaining founding member organizations and organizations recognized by WOSM as national scout organizations. WOSM's rules protect its founding and existing member organizations by permitting only one member organization in each country and locking-out all other Scout organizations from WOSM membership, recognition and participation no matter how worthy or large their membership. Several member organizations are federations, some with different component groups divided on the basis of religion (e.g., France and Denmark), ethnic identification (e.g., Israel) or language (e.g., Belgium). However, WOSM has never required an existing member organization to federate with other Scout organizations in the country, in order to make WOSM more inclusive and representative. There are numerous Canadian Scout organizations but only one is a WOSM member organization (the Canadian branch of one of the organizations that founded WOSM) which has a French language affiliate which is thereby recognized by WOSM. Other than this inherent limitation on WOSM membership, the basis for WOSM membership includes adherence to WOSM's aims and principles and independence from political involvement on the part of each member organization.

The decline in wild fish stocks has increased the demand for farmed fish. However, finding alternative sources of protein and oil for fish feed is necessary so the aquaculture industry can grow sustainably; otherwise, it represents a great risk for the over-exploitation of forage fish. Aquaculture production now exceeds capture fishery production and together the relative GDP contribution has ranged from 0.01 to 10%. Singling out aquaculture's relative contribution to GDP, however, is not easily derived due to lack of data. Another recent issue following the banning in 2008 of organotins by the International Maritime Organization is the need to find environmentally friendly, but still effective, compounds with antifouling effects. Many new natural compounds are discovered every year, but producing them on a large enough scale for commercial purposes is almost impossible. It is highly probable that future developments in this field will rely on microorganisms, but greater funding and further research is needed to overcome the lack of knowledge in this field.

Urotensin II-related peptide (URP) is a hormone that in humans is encoded by the gene UTS2B. URP is a cyclic neuropeptide that is found in all vertebrates that have been genome sequenced so far. It has a long lasting hypotensive effect and may also regulate reproduction. It is part of the Urotensin II system and is one of the two endogenous ligands for rats, mice, and possibly humans.

== Plot == On the day of her first wedding anniversary, Pallavi travels from San Francisco to Los Angeles to meet her former lover, P. Uma Maheswara Rao, unbeknownst to her husband, Arun. Eighteen months earlier, college-going Pallavi aspires to record a dance performance to show her future family post-marriage. Lacking natural skill, she hires Uma, an orphaned statistics student, to tutor her. Over time, Uma helps Pallavi with her dance, assists her in confronting a bully, and the two fall in love. Pallavi arranges for Uma to stay in her family's penthouse, where he tutors local students to earn money. When her family begins seeking marital alliances, Pallavi proposes eloping. Uma initially agrees, but backs out after witnessing Pallavi's father, Chandramouli, lecture a young boy on the financial and emotional responsibilities of marriage. Realizing he needs stability, Uma leaves for New Delhi to pursue a Ph.D., asking Pallavi to wait. Heartbroken and pressured to marry, Pallavi severs contact and eventually agrees to marry her suitor Arun. A year later, Pallavi learns from Uma's former professor that Uma has fallen into severe depression and alcoholism. Feeling responsible, she travels to Los Angeles to confront him. In Los Angeles, Pallavi insists she is happily married, but Uma refuses to believe her. To prove her happiness, Pallavi invites Uma to stay with her and Arun in San Francisco for 10 days with Arun's consent. Uma accepts on the condition that if he fails to see genuine love between the couple, Pallavi must leave him.

Sources: en.wikipedia.org

Background from the literature

Additionally, it reacts with NADPH-dependent acetoacetyl-coenzyme A reductase, also known as PhaB, in a pathway that produces polyester polyhydroxyalkanoate (PHA). The reduction of acetoacetyl-coA by Pha creates (R)-3-hydroxybutyryl-CoA, which polymerizes to PHA. The pathway is present in bacteria such as Ralstonia eutropha and the PCC6803 strain of Synechocystis. Mover over, Acetoacetyl-CoA is involved with neuronal development involving lipogenesis and providing fats and cholesterol for neuronal cells.

Under the Basel III programme, created by an international banker group, banks must hold more money in reserves based on the risk-profile that it holds, as determined by the member state regulator. More risky assets require more reserves, and the Capital Requirements Regulation 2013 codifies these standards, for instance by mandating that proportionally less in reserves is needed if more government debt is held, but more if mortgage-backed securities are held. To guard against the risk of bank runs, the Deposit Guarantee Directive 2014 creates an EU wide minimum guarantee of €100,000 for bank deposits, so that if anyone's bank goes insolvent, the state will pay the deposit up to this amount. There are not yet rules requiring higher reserving and accounting practices for climate risk and of gas, oil or coal reserves become worthless as Europe replaces fossil fuels with renewable energy.

by sending weapons to one of the sides) between Russia and Ukraine to negotiate an end to the conflict and invited the US to join Brazil in a new global climate governance On 28 February, Brazilian Environment minister Marina Silva met with John Kerry, the White House envoy for climate change during his visit to Brazil, and announced the resumption of a US-Brazil environment group created in 2015 to debate energy transition, low carbon economy, climate change mitigation, indigenous peoples protection and bioconomy among others between the two countries. Nevertheless, no contribution to the Amazon Fund was announced by Kerry during the visit. In September 2023, Lula and Biden met on the sidelines of the 78th United National General Assembly (UNGA), in New York, to launch an initiative to promote worker's rights. In June 2024, it was reported that Brazil and the US were preparing to launch a joint green transition partnership involving lithium, niobium and other strategic minerals to expand and develop both countries' supply chains.

== History == The drug was invented by Ciba-Geigy (now Novartis) in the early 1980s and sold to Jenner Biotherapies in the 1990s. In 2003, IDM Pharma bought the rights and developed it further. IDM Pharma was acquired by Takeda along with mifamurtide in June 2009. Mifamurtide had already been granted orphan drug status by the U.S. Food and Drug Administration (FDA) in 2001, and the European Medicines Agency (EMA) followed in 2004. It was approved in the 27 European Union member states plus Iceland, Liechtenstein, and Norway by a centralized marketing authorization in March 2009. The drug was denied approval by the FDA in 2007. Mifamurtide has been licensed by the EMA since March, 2009.

In 2004, development of an antisense therapy for spinal muscular atrophy began. Over the following years, an antisense oligonucleotide later named nusinersen was developed by Ionis Pharmaceuticals under a licensing agreement with Biogen. In December 2016, nusinersen received regulatory approval from FDA and soon after, from other regulatory agencies worldwide. As of 2020, more than 50 antisense oligonucleotides were in clinical trials, including over 25 in advanced clinical trials (phase II or III). A follow-on drug to Inotersen is being developed by Ionis Pharmaceuticals and under license to Akcea Therapeutics for hereditary transthyretin-mediated amyloidosis. In this formulation the ASO is conjugated to N-Acetylgalactosamine enabling hepatocyte-specific delivery, greatly reducing dose requirements and side effect profile while increasing the level of transthyretin reduction in patients.

Sources: en.wikipedia.org

Frequently asked questions